Use of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Patients with Metastatic Colorectal Cancer: A Single Center Experience
| Autor: | ŞAHİNGÖZ ERDAL, Gülçin, GÜLTÜRK, İlkay, ÖZMEN, Aykut, TACAR, Seher Yıldız, YILMAZ, Mesut, TURAL, Deniz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Volume: 39, Issue: 4 1112-1119 Journal of Experimental and Clinical Medicine |
| ISSN: | 1309-4483 1309-5129 |
| Popis: | Introduction: Despite all the advances in therapeutic modalities, Colorectal Cancer(CRC) continues to be the fourth most common cause of cancer-related deaths. The aim of this study was to share our experiences regarding the usage rates of monoclonal antibodies(mAbs) (such as Bevacizumab, Cetuximab, and Panitumumab), overall survival(OS) and progression-free survival(PFS) in patients with metastaticCRC(mCRC). Material metod: This retrospective study included 210 patients with mCRC who were followed up in our hospital's oncology clinic between January 2010 and October 2020 and who received mAb treatment, regardless of their stage at the time of diagnosis.Results: Fifty-two(24.8%) of the patients received a treatment regimen with Cetuximab and 46 with Panitumumab mAb, 29 patients(17.8%) received Cetuximab and Bevacizumab mAb treatment at different times, and 22 patients received Panitumumab and Bevacizumab mAb treatment, 112 of the patients received only Bevacizumab treatment. Panitumumab and Cetuximab mAb treatment was mostly taken in the 1st lines(69.6%, 76.9%, respectively). A statistically significant difference was found between the OSs of the cases according to the mAb treatment received(p=0.001). Administration of Panitumumab and Cetuximab mAb in the 1st or 2nd series didn’t make a significant difference to PFS.Discussion: The distribution of Panitumumab and Cetuximab mAb treatments was found to be balanced. They were preferred to give it in the first line. Patients who received anti EGFR mAb treatment had longer OS and PFS duration than those who received anti VEGF mAb only. It can be said that taking anti EGFR mAb treatment(being KRAS WT) has a positive effect on prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|